共 114 条
[1]
Aldoss I(2018)Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia Haematologica 103 e404-e407
[2]
Yang D(2021)Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice Am J Hematol 96 790-795
[3]
Aribi A(2010)Relapse after allogeneic stem cell transplantation Expert Rev Hematol 3 429-441
[4]
Apel A(2020)Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial Lancet Haematol 7 e28-e39
[5]
Moshe Y(2012)Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning Bone Marrow Transplant 47 1171-1177
[6]
Ofran Y(2018)Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies Am J Hematol 93 401-407
[7]
Barrett AJ(2020)Azacitidine and venetoclax in previously untreated acute myeloid leukemia N Engl J Med 383 617-629
[8]
Battiwalla M(2021)Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia J Clin Oncol 39 2768-2778
[9]
Beelen DW(2017)Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel Blood 129 424-447
[10]
Trenschel R(2015)International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts Blood 126 291-299